Ad4-EnvC150 HIV vaccine / Emergent Biosolutions - LARVOL DELTA

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults (clinicaltrials.gov) - P1 | N=20 | Terminated | Sponsor: Emergent BioSolutions | N=60 ➔ 20 | Unknown status ➔ Terminated; Study endpoints not met.

Combination therapy • Enrollment change • Trial termination • Human Immunodeficiency Virus • Infectious Disease